Salarius Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
DCOY$1.10-2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| (Unaudited) | (Audited) | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $794,886 | $2,434,528 |
| Prepaid expenses and other current assets | 564,692 | 553,034 |
| Total current assets | 1,359,578 | 2,987,562 |
| Other assets | 33,200 | 35,412 |
| Total assets | $1,392,778 | $3,022,974 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $1,481,949 | $936,994 |
| Accrued expenses and other current liabilities | 740,553 | 352,419 |
| Notes payable | — | 221,866 |
| Total liabilities | 2,222,502 | 1,511,279 |
| Commitments and contingencies (Note 4) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 0 issued and outstanding | — | — |
| Common stock, $0.0001 par value; 100,000,000 shares authorized; 2,127,286 and 1,441,157 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively | 213 | 144 |
| Additional paid-in capital | 83,761,039 | 83,435,169 |
| Accumulated deficit | (84,590,976) | (81,923,618) |
| Total stockholders' equity (deficit) | (829,724) | 1,511,695 |
| Total liabilities and stock holders'equity (deficit) | $1,392,778 | $3,022,974 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.